Epigenetics in cancer: implications for early detection and prevention

被引:106
作者
Verma, M [1 ]
Srivastava, S [1 ]
机构
[1] NCI, Canc Biomarkers Res Grp, Div Canc Prevent, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S1470-2045(02)00932-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Knowledge of the molecular events that occur during the early stages of cancer has advanced rapidly. The initiation and development of cancer involves several molecular changes, which include epigenetic alterations. Epigenetics is the study of modifications in gene expression that do not involve changes in DNA nucleotide sequences. Modifications in gene expression through methylation of DNA and remodelling of chromatin via histone proteins are believed to be the most important of the epigenetic changes. The study of epigenetics offers great potential for the identification of biomarkers that can be used to detect and diagnose cancer in its earliest stages and to accurately assess individual risk. There has been a recent surge of interest among researchers as variations in the methylation of DNA have been shown to be the most consistent molecular changes in many neoplasms. An important distinction between a genetic and an epigenetic change in cancer is that epigenetic changes can be reversed more easily by use of therapeutic interventions. The discovery of these basic premises should stimulate much future research on epigenetics.
引用
收藏
页码:755 / 763
页数:9
相关论文
共 74 条
[41]   The role of epigenetics in cancer - DNA methylation, Imprinting and the Epigenetics of Cancer - An American Association for Cancer Research Special Conference - Las Croabas, Puerto Rico, 12-16 1997 December [J].
Lengauer, C ;
Issa, JP .
MOLECULAR MEDICINE TODAY, 1998, 4 (03) :102-103
[42]  
Lin XH, 2001, CANCER RES, V61, P8611
[43]   INACTIVATION OF THE TYPE-II TGF-BETA RECEPTOR IN COLON-CANCER CELLS WITH MICROSATELLITE INSTABILITY [J].
MARKOWITZ, S ;
WANG, J ;
MYEROFF, L ;
PARSONS, R ;
SUN, LZ ;
LUTTERBAUGH, J ;
FAN, RS ;
ZBOROWSKA, E ;
KINZLER, KW ;
VOGELSTEIN, B ;
BRATTAIN, M ;
WILLSON, JKV .
SCIENCE, 1995, 268 (5215) :1336-1338
[44]  
Mintz A, 2000, CRIT REV ONCOGENESIS, V11, P77
[45]  
Momparler RL, 1997, LEUKEMIA, V11, pS1
[46]   Alteration of N-acetylglucosaminyltransferases in pancreatic carcinoma [J].
Nan, BC ;
Shao, DM ;
Chen, HL ;
Huang, Y ;
Gu, JX ;
Zhang, YB ;
Wu, ZG .
GLYCOCONJUGATE JOURNAL, 1998, 15 (10) :1033-1037
[47]   Preneoplastic prostate lesions - An opportunity for prostate cancer prevention [J].
Nelson, WG ;
De Marzo, AM ;
Deweese, TL ;
Lin, XH ;
Brooks, JD ;
Putzi, MJ ;
Nelson, CP ;
Groopman, JD ;
Kensler, TW .
CANCER PREVENTION: MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS, 2001, 952 :135-144
[48]   The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention [J].
Nelson, WG ;
De Marzo, AM ;
DeWeese, TL .
UROLOGY, 2001, 57 (4A) :39-45
[49]   MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex [J].
Ng, HH ;
Zhang, Y ;
Hendrich, B ;
Johnson, CA ;
Turner, BM ;
Erdjument-Bromage, H ;
Tempst, P ;
Reinberg, D ;
Bird, A .
NATURE GENETICS, 1999, 23 (01) :58-61
[50]   Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report [J].
Piekarz, RL ;
Robey, R ;
Sandor, V ;
Bakke, S ;
Wilson, WH ;
Dahmoush, L ;
Kingma, DM ;
Turner, ML ;
Altemus, R ;
Bates, SE .
BLOOD, 2001, 98 (09) :2865-2868